Bausch Health Companies ( (BHC) ) has released its Q4 earnings. Here is a breakdown of the information Bausch Health Companies presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Bausch Health Companies Inc. is a global pharmaceutical company known for its diverse portfolio in the healthcare sector, focusing on areas such as gastroenterology, eye health, and dermatology. In its latest earnings report, Bausch Health announced robust financial results for the fourth quarter and full year of 2024, marking the seventh consecutive quarter of revenue and adjusted EBITDA growth. The company reported consolidated revenues of $2.56 billion for the quarter and $9.63 billion for the year, with significant contributions from all business segments including Bausch + Lomb and Solta Medical.
The financial performance of Bausch Health in 2024 was marked by a 10% increase in reported annual revenues and an 8% organic growth rate, highlighting strong performance across all segments. The company achieved a quarterly net income of $93 million and an annual net loss of $46 million, which was a substantial improvement from the previous year’s loss. The adjusted EBITDA for the year rose by 10% to $3.31 billion, driven by higher sales and strategic investments.
Segment-wise, the Salix and Solta Medical segments showed significant growth, with Solta Medical experiencing a 34% revenue increase in Q4. The Bausch + Lomb segment also saw a 16% rise in annual revenues. The company’s international segment faced challenges with a slight decline in Q4 but still achieved a 4% annual increase. Operational income improvements were noted due to increased sales and reduced impairment charges.
Looking ahead, Bausch Health is optimistic about 2025, projecting revenue growth of 2% to 6% and adjusted EBITDA growth of 3% to 7%. The company is focusing on strategic initiatives and exploring capital market opportunities to address debt obligations, positioning itself to capitalize on future growth and innovation in the healthcare sector.
